Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical finasteride nanoemulgel 0.25% for mild to moderate androgenetic alopecia
IRCT20190210042676N22Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of finasteride in androgenetic alopecia (AGA), sponsored by Tehran University of Medical Sciences. Primary endpoints: Hair count changes and Hair loss change. Started May 2022; status: completed.
02
Drugs
finasteride
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT20190210042676N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190210042676N22.